Table of Contents
ISRN Family Medicine
Volume 2013 (2013), Article ID 638469, 15 pages
http://dx.doi.org/10.5402/2013/638469
Review Article

Tramadol/Paracetamol Fixed-Dose Combination for Chronic Pain Management in Family Practice: A Clinical Review

1Centro de Salud Universitario Goya, c/O’Donnell 55, 28009 Madrid, Spain
2Johns Hopkins University, Baltimore, MD 21287, USA
3Association of Chronic Pain Patients, Houston, TX 77515, USA
4Arthritis Center Twente (MST & UT), P.O. Box 50.000, 7500KA Enschede, The Netherlands
5Department of Endocrinology, Diabetology and Osteology, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland
6Kansas University Medical Center, Kansas City, KS 66160, USA
7International Clinic Research, Overland Park, KS 66210, USA
8Department of Pain Medicine, Beaumont Hospital, Beaumont, Dublin 9, Ireland
9Service de Médecine Interne et Consultation de la Douleur, Hôpital Dieu, 75004 Paris, France
10Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA 19140, USA

Received 30 January 2013; Accepted 19 February 2013

Academic Editors: D. Fung and C. Pearce

Copyright © 2013 Ignacio Morón Merchante et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. H. Frießem, A. Willweber-Strumpf, and M. W. Zenz, “Chronic pain in primary care. German figures from 1991 and 2006,” BMC Public Health, vol. 9, article 299, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Mäntyselkä, E. Kumpusalo, R. Ahonen et al., “Pain as a reason to visit the doctor: a study in Finnish primary health care,” Pain, vol. 89, no. 2-3, pp. 175–180, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. K. J. Reid, J. Harker, M. M. Bala et al., “Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact,” Current Medical Research and Opinion, vol. 27, no. 2, pp. 449–462, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Breivik, B. Collett, V. Ventafridda, R. Cohen, and D. Gallacher, “Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment,” European Journal of Pain, vol. 10, no. 4, pp. 287–333, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. P. C. Langley, “The prevalence, correlates and treatment of pain in the European Union,” Current Medical Research and Opinion, vol. 27, no. 2, pp. 463–480, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. Institute of Medicine Report from the Committee on Advancing Pain Research, Care, Education, Relieving Pain in America, A Blueprint for Transforming Prevention, Care, Education and Research, The National Academies Press, 2011.
  7. D. Schopflocher, P. Taenzer, and R. Jovey, “The prevalence of chronic pain in Canada,” Pain Research & Management, vol. 16, no. 6, pp. 445–450, 2011. View at Google Scholar
  8. C. Toth, J. Lander, and S. Wiebe, “The prevalence and impact of chronic pain with neuropathic pain symptoms in the general population,” Pain Medicine, vol. 10, no. 5, pp. 918–929, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. F. M. Blyth, L. M. March, A. J. M. Brnabic, L. R. Jorm, M. Williamson, and M. J. Cousins, “Chronic pain in Australia: a prevalence study,” Pain, vol. 89, no. 2-3, pp. 127–134, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. C. H. Dominick, F. M. Blyth, and M. K. Nicholas, “Unpacking the burden: understanding the relationships between chronic pain and comorbidity in the general population,” Pain, vol. 153, no. 2, pp. 293–304, 2012. View at Google Scholar
  11. P. Langley, G. Müller-Schwefe, A. Nicolaou, H. Liedgens, J. Pergolizzi, and G. Varrassi, “The societal impact of pain in the European Union: health-related quality of life and healthcare resource utilization,” Journal of Medical Economics, vol. 13, no. 3, pp. 571–581, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Langley, G. Müller-Schwefe, A. Nicolaou, H. Liedgens, J. Pergolizzi, and G. Varrassi, “The impact of pain on labor force participation, absenteeism and presenteeism in the European Union,” Journal of Medical Economics, vol. 13, no. 4, pp. 662–672, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. U. Jakobsson, “The epidemiology of chronic pain in a general population: results of a survey in southern Sweden,” Scandinavian Journal of Rheumatology, vol. 39, no. 5, pp. 421–429, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. S. T. Brown, M. K. Kirkpatrick, M. S. Swanson, and I. L. McKenzie, “Pain experience of the elderly,” Pain Management Nursing, vol. 12, no. 4, pp. 190–196, 2011. View at Google Scholar
  15. R. Baron, A. Binder, and G. Wasner, “Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment,” The Lancet Neurology, vol. 9, no. 8, pp. 807–819, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. R. H. Dworkin, D. C. Turk, J. T. Farrar et al., “Core outcome measures for chronic pain clinical trials: IMMPACT recommendations,” Pain, vol. 113, no. 1-2, pp. 9–19, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Wilson and M. J. Hockenberry, Wong’s Clinical Manual of Pediatric Nursing, Elsevier Mosby, St Louis, Mo, USA, 8th edition, 2008.
  18. R. Freynhagen, R. Baron, U. Gockel, and T. R. Tölle, “painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain,” Current Medical Research and Opinion, vol. 22, no. 10, pp. 1911–1920, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Bouhassira, N. Attal, H. Alchaar et al., “Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4),” Pain, vol. 114, no. 1-2, pp. 29–36, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Bennett, “The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs,” Pain, vol. 92, no. 1-2, pp. 147–157, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. M. L. Haanpää, M. M. Backonja, M. I. Bennett et al., “Assessment of neuropathic pain in primary care,” American Journal of Medicine, vol. 122, no. 10, supplement, pp. S13–S21, 2009. View at Google Scholar
  22. International Association for the Study of Pain, “Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy,” Pain, vol. 3, supplement, pp. S1–S226, 1986. View at Google Scholar
  23. H. Merskey and N. Bogduk, Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms, IASP Press, Seattle, WA, USA, 1994.
  24. N. Schmitt and H. U. Gerbershagen, “The Mainz Staging System (MPSS) for chronic pain,” Pain, vol. 41, supplement 5, p. S484, 1990. View at Google Scholar
  25. German Pain Questionnaire, 2012, http://www.dgss.org/deutscher-schmerzfragebogen/.
  26. J. Pergolizzi, K. Ahlbeck, D. Aldington et al., “The chronic pain conundrum: should we CHANGE from relying on past history to assessing prognostic factors?” Current Medical Research and Opinion, vol. 28, no. 2, pp. 249–256, 2012. View at Google Scholar
  27. B. Collett, “The burden of chronic pain,” Current Medical Research and Opinion, vol. 27, pp. 2065–2066, 2011. View at Google Scholar
  28. J. E. Ware Jr. and C. D. Sherbourne, “The MOS 36-item short-form health survey (SF-36)—I. Conceptual framework and item selection,” Medical Care, vol. 30, no. 6, pp. 473–483, 1992. View at Google Scholar · View at Scopus
  29. S. H. Lovibond and P. F. Lovibond, Manual for the Depression Anxiety Stress Scales, Psychology Foundation, Sydney, Australia, 2nd edition, 1995.
  30. A. T. Beck, W. Y. Rial, and K. Rickels, “Short form of depression inventory: cross validation,” Psychological Reports, vol. 34, no. 3, pp. 1184–1186, 1974. View at Google Scholar · View at Scopus
  31. N. Bellamy, W. W. Buchanan, C. H. Goldsmith, J. Campbell, and L. W. Stitt, “Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee,” Journal of Rheumatology, vol. 15, no. 12, pp. 1833–1840, 1988. View at Google Scholar · View at Scopus
  32. N. Bellamy, WOMAC Osteoarthritis Index: User Guide IX, Queensland, Brisbane, Australia, 2009.
  33. G. Müller-Schwefe, W. Jaksch, B. Morlion et al., “Make a CHANGE: optimising communication and pain management decisions,” Current Medical Research and Opinion, vol. 27, no. 2, pp. 481–488, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. J. E. Ware, M. Kosinski, and S. D. Keller, “A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity,” Medical Care, vol. 34, no. 3, pp. 220–233, 1996. View at Google Scholar · View at Scopus
  35. R. Melzack, “The short-form McGill Pain Questionnaire,” Pain, vol. 30, no. 2, pp. 191–197, 1987. View at Google Scholar · View at Scopus
  36. C. S. Cleeland and K. M. Ryan, “Pain assessment: global use of the Brief Pain Inventory,” Annals of the Academy of Medicine Singapore, vol. 23, no. 2, pp. 129–138, 1994. View at Google Scholar · View at Scopus
  37. The EuroQoL Group, “EuroQol—a new facility for the measurement of health-related quality of life,” Health Policy, vol. 16, pp. 199–208, 1990. View at Google Scholar
  38. K. D. Brandt, S. A. Mazzuca, and K. A. Buckwalter, “Acetaminophen, like conventional NSAIDs, may reduce synovitis in osteoarthritic knees,” Rheumatology, vol. 45, no. 11, pp. 1389–1394, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Flood, “The role of acetaminophen in the treatment of osteoarthritis,” The American Journal of Managed Care, vol. 16, pp. S48–S54, 2010. View at Google Scholar · View at Scopus
  40. H. S. Smith, “Potential analgesic mechanisms of acetaminophen,” Pain Physician, vol. 12, no. 1, pp. 269–280, 2009. View at Google Scholar · View at Scopus
  41. W. Zhang, G. Nuki, R. W. Moskowitz et al., “OARSI recommendations for the management of hip and knee osteoarthritis—part III: changes in evidence following systematic cumulative update of research published through January 2009,” Osteoarthritis and Cartilage, vol. 18, no. 4, pp. 476–499, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Schilling, R. Corey, M. Leonard, and B. Eghtesad, “Acetaminophen: old drug, new warnings,” Cleveland Clinic Journal of Medicine, vol. 77, no. 1, pp. 19–27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. W. M. Lee, “Etiologies of acute liver failure,” Seminars in Liver Disease, vol. 28, no. 2, pp. 142–152, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. FDA, “Assessment of safety of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs),” 2012, http://www.fda.gov/ohrms/dockets/ac/02/briefing/3882B2_02_McNeil-NSAID.htm.
  45. Electronic medicines compendium, “Diclofenac sodium 50 mg tablets,” 2012, http://www.medicines.org.uk/emc/medicine/22653#INCOMPATIBILITIES .
  46. Electronic Medicines Compendium, “Anadin ibuprofen 200 mg tablets,” 2012, http://www.medicines.org.uk/EMC/medicine/15681/SPC/Anadin+Ibuprofen+200mg+Tablets/.
  47. Electronic Medicines Compendium, “Naproxen 250 mg tablets,” 2012, http://www.medicines.org.uk/emc/medicine/23037/SPC#INCOMPATIBILITIES.
  48. Electronic Medicines Compendium, “Celebrex 100 mg & 200 mg capsules,” 2012, http://www.medicines.org.uk/emc/medicine/14534#INCOMPATIBILITIES.
  49. American Geriatrics Society Panel, “Pharmacological management of persistent pain in older persons,” Journal of the American Geriatrics Society, vol. 57, no. 8, pp. 1331–1346, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. E. Kalso, J. E. Edwards, R. A. Moore, and H. J. McQuay, “Opioids in chronic non-cancer pain: systematic review of efficacy and safety,” Pain, vol. 112, no. 3, pp. 372–380, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Camilleri, “Opioid-induced constipation: challenges and therapeutic opportunities,” American Journal of Gastroenterology, vol. 106, no. 5, pp. 835–842, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Korkmazsky, J. Ghandehari, A. Sanchez, H. M. Lin, and M. Pappagallo, “Feasibility study of rapid opioid rotation and titration,” Pain Physician, vol. 14, no. 1, pp. 71–82, 2011. View at Google Scholar · View at Scopus
  53. C. Passero and M. McCaffery, “Opioid-induced hyperalgesia,” Journal of Perianesthesia Nursing, vol. 27, no. 1, pp. 46–50, 2012. View at Google Scholar
  54. J. Bacha, S. Reast, and A. Pearlstone, “Treatment practices and perceived challenges for European physicians treating opioid dependence,” Heroin Addiction and Related Clinical Problems, vol. 12, no. 3, pp. 9–19, 2010. View at Google Scholar · View at Scopus
  55. D. H. Angres and K. Bettinardi-Angres, “The disease of addiction: origins, treatment, and recovery,” Disease-a-Month, vol. 54, no. 10, pp. 696–721, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. W. Ling, L. Mooney, and M. Hillhouse, “Prescription opioid abuse, pain and addiction: clinical issues and implications,” Drug and Alcohol Review, vol. 30, no. 3, pp. 300–305, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. J. P. Schneider, M. Matthews, and R. N. Jamison, “Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?” CNS Drugs, vol. 24, no. 10, pp. 805–810, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. R. B. Raffa and J. V. Pergolizzi, “Opioid formulations designed to resist/deter abuse,” Drugs, vol. 70, no. 13, pp. 1657–1675, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Pergolizzi, R. H. Böger, K. Budd et al., “Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used world health organization step III opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine, Oxycodone),” Pain Practice, vol. 8, no. 4, pp. 287–313, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. R. B. Raffa and E. Friderichs, “The basic science aspect of tramadol hydrochloride,” Pain Reviews, vol. 3, no. 4, pp. 249–271, 1996. View at Google Scholar · View at Scopus
  61. R. B. Raffa, R. J. Tallarida, R. Taylor Jr., and J. V. Pergolizzi Jr., “Fixed-dose combinations for emerging treatment of pain,” Expert Opinion on Pharmacotherapy, vol. 13, no. 9, pp. 1261–1270, 2012. View at Google Scholar
  62. E. A. Shipton, “Tramadol—present and future,” Anaesthesia and Intensive Care, vol. 28, no. 4, pp. 363–374, 2000. View at Google Scholar · View at Scopus
  63. W. Leppert and J. Łuczak, “The role of tramadol in cancer pain treatment—a review,” Supportive Care in Cancer, vol. 13, no. 1, pp. 5–17, 2005. View at Google Scholar
  64. J. V. Pergolizzi Jr., R. Taylor Jr., and R. B. Raffa, “Extended-release formulations of tramadol in the treatment of chronic pain,” Expert Opinion on Pharmacotherapy, vol. 12, no. 11, pp. 1757–1768, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. Electronic Medicines Compendium, “Tramadol hydrochloride 50 mg capsules,” 2012, http://www.medicines.org.uk/emc/medicine/24186/SPC/tramadol%20hydrochloride%2050mg%20capsules/.
  66. L. J. Scott and C. M. Perry, “Tramadol: a review of its use in perioperative pain,” Drugs, vol. 60, no. 1, pp. 139–176, 2000. View at Google Scholar · View at Scopus
  67. L. L. Jorge, C. C. Feres, and V. E. P. Teles, “Topical preparations for pain relief: efficacy and patient adherence,” Journal of Pain Research, vol. 4, pp. 11–24, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. G. Mick and G. Correa-Illanes, “Topical pain management with the 5% lidocaine medicated plaster—a review,” Current Medical Research and Opinion, vol. 28, no. 6, pp. 937–951, 2012. View at Google Scholar
  69. S. Derry, R. A. Moore, and R. Rabbie, “Topical NSAIDs for chronic musculoskeletal pain in adults,” Cochrane Database of Systematic Reviews, vol. 9, Article ID CD007400, 2012. View at Google Scholar
  70. P. Anand and K. Bley, “Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch,” British Journal of Anaesthesia, vol. 107, no. 4, pp. 490–502, 2011. View at Google Scholar
  71. M. L. Haanpää, G. K. Gourlay, J. L. Kent et al., “Treatment considerations for patients with neuropathic pain and other medical comorbidities,” Mayo Clinic Proceedings, vol. 85, no. 3, supplement, pp. S15–S25, 2010. View at Google Scholar
  72. G. J. Sills, “Mechanisms of action of antiepileptic drugs,” in Epilepsy 2011: From Science to Society. A Practical Guide to Epilepsy, J. W. Sander, M. C. Walker, and J. E. Smalls, Eds., ILAE, National Society for Epilepsy, London, UK, 2011. View at Google Scholar
  73. M. D. Sullivan and J. P. Robinson, “Antidepressant and anticonvulsant medication for chronic pain,” Physical Medicine and Rehabilitation Clinics of North America, vol. 17, no. 2, pp. 381–400, 2006. View at Publisher · View at Google Scholar · View at Scopus
  74. R. H. Dworkin, A. B. O’Connor, J. Audette et al., “Recommendations for the pharmacological management of neuropathic pain: an overview and literature update,” Mayo Clinic Proceedings, vol. 85, supplement 3, pp. S3–S14, 2010. View at Google Scholar
  75. American Geriatrics Society 2012 Beers Criteria Update Expert Panel, “American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults,” Journal of the American Geriatrics Society, vol. 60, no. 4, pp. 616–631, 2012. View at Google Scholar
  76. F. Buttgereit, G. R. Burmester, R. H. Straub, M. J. Seibel, and H. Zhou, “Exogenous and endogenous glucocorticoids in rheumatic diseases,” Arthritis and Rheumatism, vol. 63, no. 1, pp. 1–9, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. J. M. Grossman, R. Gordon, V. K. Ranganath et al., “American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis,” Arthritis Care & Research, vol. 62, no. 11, pp. 1515–1526, 2010. View at Google Scholar · View at Scopus
  78. D. Franchimont, “Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies,” Annals of the New York Academy of Sciences, vol. 1024, pp. 124–137, 2004. View at Publisher · View at Google Scholar · View at Scopus
  79. D. Huscher, K. Thiele, E. Gromnica-Ihle et al., “Dose-related patterns of glucocorticoid-induced side effects,” Annals of the Rheumatic Diseases, vol. 68, no. 7, pp. 1119–1124, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. M. C. Lansang and L. Kramer Hustak, “Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them,” Cleveland Clinic Journal of Medicine, vol. 78, no. 11, pp. 748–756, 2011. View at Google Scholar
  81. NICE, “Rheumatoid arthritis: the management of rheumatoid arthritis in adults,” NICE, London, UK, 2009, http://www.nice.org.uk/nicemedia/live/12131/43327/43327.pdf.
  82. S. Perrot, D. Krause, P. Crozes, and C. Naïm, “Efficacy and tolerability of paracetamol/tramadol (325 mg/37.5 mg) combination treatment compared with tramadol (50 mg) monotherapy in patients with subacute low back pain: a multicenter, randomized, double-blind, parallel-group, 10-day treatment study,” Clinical Therapeutics, vol. 28, no. 10, pp. 1592–1606, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. N. Rawal, V. Macquaire, E. Catala, M. Berti, R. Costa, and M. Wietlisbach, “Tramadol/paracetamol combination tablet for postoperative pain following ambulatory hand surgery: a double-blind, double-dummy, randomized, parallel-group trial,” Journal of Pain Research, vol. 4, pp. 103–110, 2011. View at Google Scholar
  84. J. Filitz, H. Ihmsen, W. Günther et al., “Supra-additive effects of tramadol and acetaminophen in a human pain model,” Pain, vol. 136, no. 3, pp. 262–270, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. W. S. Mullican and J. R. Lacy, “Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial,” Clinical Therapeutics, vol. 23, no. 9, pp. 1429–1445, 2001. View at Publisher · View at Google Scholar · View at Scopus
  86. A. Serrie, H. Ganry, A. Creuzé, and B. Schatz, “Epidemiological data, efficacy and safety on a fixed combination of paracetamol (325 mg) and tramadol (37.5 mg) in the treatment of moderate to severe pain, in general practice (ELZA survey: Efficacite et To Lerance de ZAldiar),” Journal of Applied Therapeutic Research, vol. 8, no. 1, pp. 3–14, 2011. View at Google Scholar · View at Scopus
  87. O. Mejjad, A. Serrie, and H. Ganry, “Epidemiological data, efficacy and safety of a paracetamol-tramadol fixed combination in the treatment of moderate-to-severe pain. SALZA: a post-marketing study in general practice,” Current Medical Research and Opinion, vol. 27, no. 5, pp. 1013–1020, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. L. Alwine, “Long-term (2-year) analgesic efficacy of tramadol/acetaminophen tablets,” Nice, France, European League Against Rheumatism (EULAR) Congress, 2000.
  89. L. Busija, L. Bridgett, S. R. M. Williams et al., “Osteoarthritis,” Best Practice and Research: Clinical Rheumatology, vol. 24, no. 6, pp. 757–768, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. L. Mandl, “Treating the pain of osteoarthritis—where do we go from here?” Journal of Rheumatology, vol. 38, no. 8, pp. 1535–1537, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. P. J. Mease, S. Hanna, E. P. Frakes, and R. D. Altman, “Pain mechanisms in osteoarthritis: understanding the role of central pain and current approaches to its treatment,” Journal of Rheumatology, vol. 38, no. 8, pp. 1546–1551, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. S. M. Seed, K. C. Dunican, and A. M. Lynch, “Osteoarthritis: a review of treatment options,” Geriatrics, vol. 64, no. 10, pp. 20–29, 2009. View at Google Scholar · View at Scopus
  93. W. Zhang, R. Moskowitz, G. Nuki et al., “OARSI recommendations for the management of hip and knee osteoarthritis—part 2: OARSI evidence-based, expert consensus guidelines,” Osteoarthritis and Cartilage, vol. 16, no. 2, pp. 137–162, 2008. View at Google Scholar
  94. NICE, “Osteoarthritis: the care and management of osteoarthritis in adults,” National Institute for Health and Clinical Excellence, London, UK, 2008, http://www.nice.org.uk/nicemedia/pdf/CG59NICEguideline.pdf.
  95. M. C. Hochberg, R. D. Altman, K. T. April et al., “American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee,” Arthritis Care and Research, vol. 64, no. 4, pp. 455–474, 2012. View at Google Scholar
  96. J. C. Silverfield, M. Kamin, S. C. Wu, and N. Rosenthal, “Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double-blind, placebo-controlled, parallel-group, add-on study,” Clinical Therapeutics, vol. 24, no. 2, pp. 282–297, 2002. View at Publisher · View at Google Scholar · View at Scopus
  97. R. Emkey, N. Rosenthal, S. C. Wu, D. Jordan, and M. Kamin, “Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial,” Journal of Rheumatology, vol. 31, no. 1, pp. 150–156, 2004. View at Google Scholar · View at Scopus
  98. K. S. Park, J. J. Choi, W. U. Kim, J. K. Min, S. H. Park, and C. S. Cho, “The efficacy of tramadol/acetaminophen combination tablets (Ultracet) as add-on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti-inflammatory drug (NSAID),” Clinical Rheumatology, vol. 31, no. 2, pp. 317–323, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. C. B. Choi, J. S. Song, Y. M. Kang et al., “A 2-week, multicenter, randomized, double-blind, double-dummy, add-on study of the effects of titration on tolerability of tramadol/acetaminophen combination tablet in Korean adults with knee osteoarthritis pain,” Clinical Therapeutics, vol. 29, no. 7, pp. 1381–1389, 2007. View at Publisher · View at Google Scholar · View at Scopus
  100. N. R. Rosenthal, J. C. Silverfield, S. C. Wu, D. Jordan, and M. Kamin, “Tramadol/acetaminophen combination tablets for the treatment of pain associated with osteoarthritis flare in an elderly population,” Journal of the American Geriatrics Society, vol. 52, no. 3, pp. 374–380, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. O. Airaksinen, J. I. Brox, C. Cedraschi et al., “Chapter 4. European guidelines for the management of chronic nonspecific low back pain,” European Spine Journal, vol. 15, no. 2, pp. S192–S300, 2006. View at Publisher · View at Google Scholar · View at Scopus
  102. R. Freynhagen and R. Baron, “The evaluation of neuropathic components in low back pain,” Current Pain and Headache Reports, vol. 13, no. 3, pp. 185–190, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. B. Morlion, “Pharmacotherapy of low back pain: targeting nociceptive and neuropathic pain components,” Current Medical Research and Opinion, vol. 27, no. 1, pp. 11–33, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. R. Chou, A. Qaseem, V. Snow et al., “Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society,” Annals of Internal Medicine, vol. 147, no. 7, pp. 478–491, 2007. View at Google Scholar · View at Scopus
  105. NICE, “Low back pain: early management of persistent non-specific low back pain,” National Institute for Health and Clinical Excellence, London, UK, 2009, http://www.nice.org.uk/nicemedia/live/11887/44343/44343.pdf.
  106. G. E. Ruoff, N. Rosenthal, D. Jordan, R. Karim, and M. Kamin, “Tramadol/acetaminophen combination tablets for the treatment of chronic lower back pain: a multicenter, randomized, double-blind, placebo-controlled outpatient study,” Clinical Therapeutics, vol. 25, no. 4, pp. 1123–1141, 2003. View at Publisher · View at Google Scholar · View at Scopus
  107. P. M. Peloso, L. Fortin, A. Beaulieu, M. Kamin, and N. R. Rosenthal, “Analgesic efficacy and safety of tramadol/acetaminophen combination tablets (Ultracet) in treatment of chronic low back pain: a multicenter, outpatient, randomized, double blind, placebo controlled trial,” Journal of Rheumatology, vol. 31, no. 12, pp. 2454–2463, 2004. View at Google Scholar · View at Scopus
  108. E. Y. Lee, E. B. Lee, B. J. Park et al., “Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial,” Clinical Therapeutics, vol. 28, no. 12, pp. 2052–2060, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. R. Freeman, P. Raskin, D. J. Hewitt et al., “Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy,” Current Medical Research and Opinion, vol. 23, no. 1, pp. 147–161, 2007. View at Publisher · View at Google Scholar · View at Scopus
  110. S. H. Ko, H. S. Kwon, J. M. Yu et al., “Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy,” Diabetic Medicine, vol. 27, no. 9, pp. 1033–1040, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. D. L. Scott, F. Wolfe, and T. W. J. Huizinga, “Rheumatoid arthritis,” The Lancet, vol. 376, no. 9746, pp. 1094–1108, 2010. View at Publisher · View at Google Scholar · View at Scopus
  112. B. Combe, R. Landewe, C. Lukas et al., “EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT),” Annals of the Rheumatic Diseases, vol. 66, no. 1, pp. 34–45, 2007. View at Publisher · View at Google Scholar · View at Scopus
  113. R. Luqmani, S. Hennell, C. Estrach et al., “British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years),” Rheumatology, vol. 48, no. 4, pp. 436–439, 2009. View at Google Scholar · View at Scopus
  114. K. Van Acker, D. Bouhassira, D. De Bacquer et al., “Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics,” Diabetes and Metabolism, vol. 35, no. 3, pp. 206–213, 2009. View at Publisher · View at Google Scholar · View at Scopus
  115. V. Spallone, “Management of painful diabetic neuropathy: guideline guidance or jungle?” Current Diabetes Reports, vol. 12, pp. 403–413, 2012. View at Google Scholar
  116. V. Bril, J. D. England, G. M. Franklin et al., “Evidence-based guideline: treatment of painful diabetic neuropathy—report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation,” Muscle and Nerve, vol. 43, no. 6, pp. 910–917, 2011. View at Publisher · View at Google Scholar · View at Scopus
  117. N. Attal, G. Cruccu, R. Baron et al., “EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision,” European Journal of Neurology, vol. 17, no. 9, pp. 1113–1123, 2010. View at Publisher · View at Google Scholar · View at Scopus
  118. ZALDIAR film-coated tablets, “Summary of Product Characteristics,” 2012, http://www.grunenthal.com/grt-web/Grunenthal_Group/Products/Zaldiar_/116100142.jsp.